Resources
23 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/3/2021 (updated 4/10/2024)
The U.S. Food and Drug Administration (FDA) announced on April 30, 2021 the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Naloxone is a medicine that can be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone is administered quickly, it can counter the opioid overdose effects, usually within minutes. A higher dose of naloxone provides an additional option in the treatment of opioid overdoses.
Posted 3/29/2024 (updated 4/4/2024)
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Mt. Vernon Square Room on Wednesday, March 4, 2020, at 4:15 PM
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Treasury Room on Wednesday, March 4, 2020, at 4:15 PM
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Monument Room on Wednesday, March 4, 2020, at 2:45 PM
Posted 7/26/2023 (updated 3/28/2024)
The FY22 RCORP-Implementation cohort is diverse and dynamic in every way, representing a wide variety of experience and possessing an unending amount of knowledge on SUD in rural areas. This session explored the different methods and practices this cohort uses in its efforts to address SUD prevention, treatment, and recovery. Participants had an opportunity to learn from and to build relationships with one another, which will, in turn strengthen, their RCORP projects. Additionally, they heard from RCORP program staff and the RCORP-Evaluation team about program updates and data utilization tools.
Posted 7/26/2023 (updated 3/28/2024)
This session focused on FY 21 RCORP-Implementation III. Grantees received an overview of the upcoming Sustainability Plan Year 2 deliverable, including a walkthrough of the template.
Posted 7/26/2023 (updated 3/28/2024)
During this session, the Fiscal Year 2020 (FY20) RCORP-Implementation grantees had an opportunity to share best practices, identify the impact that the RCORP grant had in their communities, learned how to use the data collected in the data dashboard, and network with other grantees. In addition, grantees received important information pertaining to evaluation, upcoming deliverables, sustainability and next steps.
Posted 1/19/2024 (updated 3/28/2024)
The FDA announced that the manufacturer of NARCAN 4 mg Nasal Spray products, Emergent BioSolutions, has extended the shelf-life of their product from 3 years to 4 years. This new extension of shelf-life was requested by the FDA to help prevent overdoses and reduce overdose-related deaths.